Merck reports that its experimental treatment for RSV safeguarded infants during testing, opening the door for possible approval.  

107364710 17062139992021 11 18t014239z 377529114 rc2hwq9kgx1y rtrmadp 0 merck co results MfNL12

Merck is in talks with regulators globally about the study data, aiming to make the treatment accessible for infants by the RSV season of 2025 to 2026.

   

Leave a Reply